Clene Yönetim

Yönetim kriter kontrolleri 3/4

Clene CEO'su Rob Etherington, Apr2013 tarihinde atandı, in görev süresi 11.58 yıldır. in toplam yıllık tazminatı $ 1.71M olup, şirket hissesi ve opsiyonları dahil olmak üzere 38.3% maaş ve 61.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.53% ine doğrudan sahiptir ve bu hisseler € 163.70K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3.9 yıldır.

Anahtar bilgiler

Rob Etherington

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	38.3%
CEO görev süresi	11.6yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Rob Etherington'un ücretlendirmesi Clene'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$36m
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$2m	US$654k	-US$50m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$2m	US$561k	-US$30m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	US$15m
Mar 31 2022	n/a	n/a	US$17m
Dec 31 2021	US$5m	US$510k	-US$10m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$55m
Dec 31 2020	US$498k	US$335k	-US$19m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$510k	US$335k	-US$16m
Dec 31 2018	US$465k	US$335k	-US$12m

Tazminat ve Piyasa: Rob 'nin toplam tazminatı ($USD 1.71M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 474.54K ).

Tazminat ve Kazançlar: Rob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rob Etherington (57 yo)

11.6yrs

Görev süresi

US$1,706,605

Tazminat

Mr. Robert Etherington, also known as Rob, MBA, serves as Chief Executive officer, President and Director at Clene Nanomedicine, Inc. He serves as President, Chief Executive Officer and Director at Clene...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Etherington	CEO, President & Director	11.6yrs	US$1.71m	0.53% € 163.7k
Morgan Brown	Chief Financial Officer	2.8yrs	US$993.70k	0% € 0
Mark Mortenson	Chief Science Officer	no data	US$1.38m	0.36% € 112.7k
Jerry Miraglia	General Counsel & Corporate Secretary	no data	Veri yok	Veri yok
Michael Hotchkin	Chief Development Officer	no data	Veri yok	Veri yok
Mary Mcneil	Head of Human Resources	no data	Veri yok	Veri yok
Benjamin Greenberg	Head of Medical	1.7yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 84C0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Etherington	CEO, President & Director	11.6yrs	US$1.71m	0.53% € 163.7k
David Matlin	Independent Chairman of the Board	3.9yrs	US$99.65k	5.66% € 1.8m
Reed Wilcox	Independent Director	11.7yrs	Veri yok	0.36% € 112.0k
Jonathon Gay	Independent Director	3.9yrs	US$67.50k	0.11% € 34.0k
Alison Mosca	Independent Director	5.2yrs	US$82.64k	4.96% € 1.5m
Arjun Desai	Independent Director	1.2yrs	US$31.09k	0.010% € 3.2k
Shalom Jacobovitz	Independent Director	11.7yrs	US$81.14k	0.047% € 14.6k
Matthew Kiernan	Independent Director	1.2yrs	US$29.59k	0.0053% € 1.7k
Vallerie McLaughlin	Independent Director	3.3yrs	US$65.63k	0% € 0

3.9yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 84C0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Clene Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Clene Inc., Annual General Meeting, May 29, 2024

Independent Chairman of the Board recently bought €96k worth of stock

High number of new directors

Clene Inc. Announces Executive Changes

Independent Director recently bought €232k worth of stock

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Recent updates

Third quarter 2024 earnings released: US$1.22 loss per share (vs US$0.38 loss in 3Q 2023)

New minor risk - Profitability

New minor risk - Profitability

Clene Inc. announced that it has received $7.31006 million in funding

New minor risk - Shareholder dilution

New minor risk - Profitability

Clene Inc. has completed a Follow-on Equity Offering in the amount of $3.499996 million.

Clene Inc. announced that it expects to receive $3.810506 million in funding

Clene Inc. has filed a Follow-on Equity Offering in the amount of $3.499996 million.

New major risk - Negative shareholders equity

Second quarter 2024 earnings released: US$1.06 loss per share (vs US$5.84 loss in 2Q 2023)

New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

Clene Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2) for Continued Listing on Nasdaq

Clene Inc. and Clene Nanomedicine Inc. Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS

Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome

Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg

First quarter 2024 earnings released: US$0.086 loss per share (vs US$0.15 loss in 1Q 2023)

Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver

Clene Inc., Annual General Meeting, May 29, 2024

Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8

New major risk - Financial position

Full year 2023 earnings released: US$0.47 loss per share (vs US$0.46 loss in FY 2022)

Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs

Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement

Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial

Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases

Independent Chairman of the Board recently bought €96k worth of stock

Third quarter 2023 earnings released: US$0.019 loss per share (vs US$0.17 loss in 3Q 2022)

Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Revenue and earnings growth

High number of new directors

Clene Inc. Announces Executive Changes

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.072 loss in 2Q 2022)

Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Independent Director recently bought €232k worth of stock

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

New major risk - Shareholder dilution

Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial

Clene Inc. has completed a Follow-on Equity Offering.

Clene Receives Non-Compliance Notice From Nasdaq

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.21 loss in 1Q 2022)

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.16 loss in FY 2021)

Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees

Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity

Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress

Clene Inc. and Clene Nanomedicine Inc. Reports Topline Results Demonstrating Survival Signal for Cnm-Au8 in Healey Als Platform Trial

Clene Inc. and its Wholly Owned Subsidiary Clene Nanomedicine Inc. Present Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Independent Director recently bought €180k worth of stock

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.055 loss in 2Q 2021)

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

Investor sentiment deteriorated over the past week

High number of new directors

Clene Inc Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

Clene Inc.(NasdaqCM:CLNN) dropped from Russell 2500 Value Index

Investor sentiment improved over the past week

Independent Chairman of the Board recently bought €145k worth of stock

Clene Inc. Announces the Presentation of New Data from the its Phase 2 RESCUE-ALS Study at the European Network to Cure ALS (ENCALS) Meeting 2022

Independent Chairman of the Board recently bought €74k worth of stock

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.66 loss in 1Q 2021)

No longer forecast to breakeven

Independent Chairman of the Board recently bought €368k worth of stock

High number of new directors

Independent Chairman of the Board recently bought €368k worth of stock

Clene Inc. and Clene Nanomedicine, Inc. Announces New Data from the Open-Label Extension of RESCUE-ALS to be Presented in a Session at the 2022 American Academy of Neurology Annual Meeting

Independent Chairman of the Board recently bought €142k worth of stock